Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
368
resultados
Última actualización
02/11/2026 [10:35:00]
Resultados 250 a 275 de 368
Resumen de: AU2026205448A1
Abstract Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a uPAR-specific chimeric antigen receptor. Also disclosed herein are methods for using the engineered immune cells of the present technology to treat or ameliorate the effects of cancer and senescence-associated pathologies (e.g., lung fibrosis, atherosclerosis, Alzheimer's disease, diabetes, liver fibrosis, chronic kidney disease, aging, or osteoarthritis) by selectively targeting senescent cells. Also provided herein are methods for detecting the senescent cell burden in a patient. Abstract
Resumen de: US20260279589A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: US20260276659A1
A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.
Resumen de: US20260276625A1
Provided is a screening method for searching for a new autophagy-inducing compound. In the present invention, a new autophagy-inducing compound is searched for using at least one of the following characteristics: (1) having high binding affinity for DEAD-box RNA helicase; (2) approximating DEAD-box RNA helicase and p62 to promote interaction; and (3) promoting droplet formation of DEAD-box RNA helicase and p62.
Resumen de: US20260274931A1
Disclosed herein are methods of conducting clinical trials in Alzheimer's disease (AD). Methods of selecting a medicament and treating an AD subject are disclosed. Methods, systems, kits, and devices for selecting a subject in AD clinical trials and treatment protocols are disclosed herein.
Resumen de: US20260276655A1
The present disclosure relates to biomarkers and uses thereof in methods for selecting a patient diagnosed with amyotrophic lateral sclerosis (ALS) for an ALS therapy. The present disclosure further relates to methods for identifying the severity of ALS in a patient, treating an ALS patient, and monitoring efficacy of an ALS treatment.
Resumen de: US20260276647A1
The present invention makes it possible to acquire biological information relating to an examination subject more easily or more accurately and to provide the biological information to a user. This living organism examination method for providing biological information relating to an examination subject (1), which is a living organism, by analyzing biological components in the sweat of the examination subject includes: a collection step (S101) for collecting sweat from an examination site of the examination subject (1); a measurement step (S102) for measuring a biological component profile of the sweat collected in the collection step; a biological information acquisition step (S103) for acquiring biological information relating to the examination subject (1) on the basis of the biological component profile measured in the measurement step; and an information provision step (S104) for providing the biological information relating to the examination subject, acquired in the biological information acquisition step, in a predetermined format.
Resumen de: US20260272867A1
The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Resumen de: US20260276634A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: US20260272907A1
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
Resumen de: WO2026192282A1
An object of the present invention is to provide a method for recommending a treatment candidate group suitable for treatment with anti-amyloid antibody therapeutics by obtaining quantitative protein analysis data from blood and selecting a patient group at high risk of conversion to dementia.
Resumen de: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Resumen de: EP4807366A2
0001 The present disclosure relates to methods, systems, and devices for performing analyses of biological nanoparticles. More specifically, the present disclosure relates to methods, systems, and devices for performing single biological nanoparticle size determination on a sample while the biological nanoparticle is in transit through a microfluidic chip. In other aspects, the present disclosure relates to methods, systems, and devices for selectively capturing biological nanoparticles on a coated planar surface, the capturing being facilitated by centrifugation.
Resumen de: WO2025041169A1
The present invention provides a kit, a device and an in-vitro assay based on a nanozyme-based lateral flow assay utilizing para-phenylenediamine of optimal concentration 0.1mM to 10mM as a chromogenic substrate for catalytically active aptamer-conjugated gold-nanozyme, which enhances sensitivity. The chromogenic substrate produces a robust brown color upon oxidation by catalytically active nanomaterial. The brown color remains stable for weeks and presents high contrast against the background. This overcomes the limitations of ordinary LFA in detecting analytes present at critical levels that are below microgram per milliliter, often resulting in false negative results. This provides a versatile and high-sensitive point-of-care diagnostic technique for rapid screening of infectious disease antigens and the detection of biomarkers for diseases such as cancer, cardiac and neurodegenerative diseases.
Resumen de: WO2025049921A1
The present disclosure provides a near full-length long read AIRR-seq (FLAIRR-Seq) method that utilizes targeted amplification by 5' rapid amplification of cDNA ends (RACE), combined with single molecule, real-time sequencing to generate highly accurate immunoglobulin (Ig) heavy chain and light chain transcripts.
Resumen de: CN122754497A
0001 本发明涉及生物医学技术领域，具体而言，本发明涉及一种检测老年痴呆的试剂盒及其应用。该试剂盒包含针对β‑淀粉样蛋白Aβ42和Aβ40的特异性单克隆抗体，其中抗人Aβ42单克隆抗体通过免疫Balb/c小鼠、细胞融合和杂交瘤筛选制备，其轻重链可变区序列如SEQ No.1‑6所示；抗人Aβ40单克隆抗体采用类似方法制备。试剂盒还包括预包被酶标板、标准品和酶标记检测抗体。通过ELISA方法检测患者外周血血清中Aβ42和Aβ40的水平，并计算Aβ42/Aβ40比值，用于阿尔兹海默症的诊断。该试剂盒具有灵敏特异、快速便捷、易于操作等特点，能有效区分阿尔兹海默症患者和抑郁症患者，适用于体外预筛查和诊断。
Resumen de: CN122750834A
本发明提供一种血管内皮细胞中SIRT7的应用、筛选药物方法及药物组合物、试剂盒、模型构建方法。血管内皮细胞中的SIRT7作为药物靶点在制备预防、延缓或治疗脑衰老和/或血管性痴呆的药物中的应用。血管内皮细胞中的SIRT7作为生物标志物在制备用于评估脑衰老程度或血管性痴呆风险的诊断试剂或试剂盒中的应用。
Resumen de: CN122749439A
本申请公开了一种有机化合物及其制备方法、作为探针的应用，属于探针领域。有机化合物具有式I所示的结构其中，arene代表芳香杂环，选自萘环、喹喔啉、苯并噻二唑中的一种；R1选自羟基、甲氧基、哌啶、吗啉、久洛尼定、氰基、硝基中的一种；R2选自氯原子、溴原子、碘原子中的一种。该探针在具有淀粉样变蛋白靶向能力的同时，在体外淀粉样模型蛋白中也表现出选择性标记的特点，可以用于阿尔茨海默病模型小鼠淀粉样沉积物的组分分析，弥补了领域内缺乏对阿尔茨海默病致病蛋白的组分分析这一空白。
Resumen de: WO2021262706A1
Provided herein are assays that provide digital measurement methods to detect proteins and other biomolecules, e.g., at low- to mid-attomolar concentrations.
Resumen de: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Resumen de: MX2025010847A
The antibody NEO-201 is shown to bind to Treg cells, and its use in targeting Treg cells is described. NEO-201 may be used for isolation, detection, or purification of active Treg cells and also to kill Treg cells. Therapeutic methods and combination therapies using NEO-201 optionally in combination with another agent are described.
Resumen de: CN122749696A
0001 本发明涉及一种与强啡肽A特异性结合的人工从头设计蛋白，所述蛋白质的氨基酸序列如SEQ ID NO:1所示。本发明针对强啡肽A具有高度柔性和动态构象的特点，通过人工从头设计方法构建具有特异性识别界面的结合蛋白，可对强啡肽A的特定序列区域或优势构象进行有效识别与结合，突破了传统“锁钥模型”难以适用于无序蛋白识别的限制。
Resumen de: KR20260135747A
본 발명은 HCN1 채널의 CNBD 도메인에 특이적으로 결합하는 세계 최초의 소분자 개방제(ind_5F_3pyr, 5-플루오로-1H-인다졸-3-일-피리딘-3-일)에 관한 것이다. 알츠하이머병에서 HCN1 채널 발현이 감소하여 신경 흥분성 이상이 발생하며, 기존 HCN 약물은 모두 차단제로서 이를 해결할 수 없다. 본 발명의 화합물은 HCN1 CNBD에 cAMP보다 강하게 결합하고(ΔG = -8.08 vs -7.51 kcal/mol), 열린 상태를 안정화하며(apo ΔG = -8.32), 혈액뇌장벽을 투과하고(MW 213, TPSA 57), TRIP8b 대체를 통한 뇌 선택성을 달성한다. 119개 후보 중 가상 스크리닝과 분자동역학으로 동정되었다. JPEGpat00001.jpg5157
Resumen de: AU2025226972A1
The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.
Nº publicación: CN122743138A 11/09/2026
Solicitante:
阿尔梅德公司
Resumen de: WO2025177848A1
The present invention addresses the problem of providing: a biomarker for determining cognitive impairment or nerve function disorder in an early stage with high accuracy; and others. In the present invention, a drebrin metabolite peptide (iMADP) selected from the below-mentioned peptides (i) to (iii) is used as a biomarker for determining cognitive impairment or nerve function disorder. (i) A peptide comprising the amino acid sequence represented by SEQ ID NO: 4; (ii) a peptide comprising the amino acid sequence represented by SEQ ID NO: 5; and (iii) a peptide which comprises an amino acid sequence having a structure such that one or more amino acid residues are deleted, substituted, and/or added in the amino acid sequence represented by SEQ ID NO: 4 or SEQ ID NO: 5.
BOPI
Sede Electrónica
